Literature DB >> 20890704

Differentiation of benign and malignant uterine corpus tumors by using proton MR spectroscopy at 3T: preliminary study.

Mayumi Takeuchi1, Kenji Matsuzaki, Masafumi Harada.   

Abstract

OBJECTIVE: To retrospectively evaluate the diagnostic ability of magnetic resonance (MR) spectroscopy for distinguishing benign and malignant lesions in patients with uterine corpus tumours at MR imaging.
METHODS: Pelvic MR spectroscopy was performed in patients with pathologically diagnosed benign and malignant uterine corpus tumours at 3T-MR imaging. Single-voxel MR spectroscopy data were collected from a single square volume of interest that encompassed the uterine corpus lesion. The total choline compounds (tCho) resonance peak areas were quantified relative to unsuppressed water using a software package. Patients who fulfilled the criteria for estimates of acceptable reliability were included.
RESULTS: A total of 32 patients (age range, 24-76 years) with 32 lesions were evaluated in this study. The median lesion size at MR imaging was 50 mm (range, 19-218 mm). A tCho peak was present in all 32 lesions including 14 malignant lesions (9.21 ± 2.21 mM), and 18 benign lesions (4.59 ± 2.22 mM) (p < 0.0001). Using a cut-off value of 7.00 mM for malignant lesions had a sensitivity of 93%, specificity of 83%, PPV of 81% and NPV of 94%.
CONCLUSION: Proton MR spectroscopy with quantitative evaluation of tCho concentration can provide helpful information in distinguishing benign and malignant uterine corpus tumours.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890704     DOI: 10.1007/s00330-010-1974-5

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  28 in total

1.  Automatic quantitation of localized in vivo 1H spectra with LCModel.

Authors:  S W Provencher
Journal:  NMR Biomed       Date:  2001-06       Impact factor: 4.044

2.  Endometrial polyps: MR imaging features and distinction from endometrial carcinoma.

Authors:  R P Grasel; E K Outwater; E S Siegelman; D Capuzzi; L Parker; S M Hussain
Journal:  Radiology       Date:  2000-01       Impact factor: 11.105

3.  Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.

Authors:  Juyoung A Jung; Fergus V Coakley; Daniel B Vigneron; Mark G Swanson; Aliya Qayyum; Vivian Weinberg; Kirk D Jones; Peter R Carroll; John Kurhanewicz
Journal:  Radiology       Date:  2004-12       Impact factor: 11.105

Review 4.  Molecular imaging of cancer: MR spectroscopy and beyond.

Authors:  K Pinker; A Stadlbauer; W Bogner; S Gruber; T H Helbich
Journal:  Eur J Radiol       Date:  2010-06-04       Impact factor: 3.528

Review 5.  Imaging the endometrium: disease and normal variants.

Authors:  K M Nalaboff; J S Pellerito; E Ben-Levi
Journal:  Radiographics       Date:  2001 Nov-Dec       Impact factor: 5.333

Review 6.  Unusual appearances of uterine leiomyomas: MR imaging findings and their histopathologic backgrounds.

Authors:  H Ueda; K Togashi; I Konishi; M L Kataoka; T Koyama; T Fujiwara; H Kobayashi; S Fujii; J Konishi
Journal:  Radiographics       Date:  1999-10       Impact factor: 5.333

7.  Hyperintense uterine myometrial masses on T2-weighted magnetic resonance imaging: differentiation with diffusion-weighted magnetic resonance imaging.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Hiromu Nishitani
Journal:  J Comput Assist Tomogr       Date:  2009 Nov-Dec       Impact factor: 1.826

8.  Human brain tumors: assessment with in vivo proton MR spectroscopy.

Authors:  D Ott; J Hennig; T Ernst
Journal:  Radiology       Date:  1993-03       Impact factor: 11.105

9.  Magnetic resonance spectroscopy features of uterine leiomyomas.

Authors:  Onder Celik; Kaya Sarac; Seyma Hascalik; Alpay Alkan; Bulent Mizrak; Saim Yologlu
Journal:  Gynecol Obstet Invest       Date:  2004-07-29       Impact factor: 2.031

Review 10.  Role of diffusion-weighted imaging in the diagnosis of gynecological diseases.

Authors:  Tomohiro Namimoto; Kazuo Awai; Takeshi Nakaura; Yumi Yanaga; Toshinori Hirai; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2008-10-07       Impact factor: 5.315

View more
  7 in total

1.  Preliminary observations and clinical value of N-acetyl resonances in ovarian tumours using in-vivo proton MR spectroscopy at 3T.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2011-08-05       Impact factor: 5.315

2.  MR Spectra of Normal Adult Testes and Variations with Age: Preliminary Observations.

Authors:  Athina C Tsili; Loukas G Astrakas; Alexandra Ntorkou; Dimitrios Giannakis; Sotirios Stavrou; Vasilios Maliakas; Nikolaos Sofikitis; Maria I Argyropoulou
Journal:  Eur Radiol       Date:  2015-10-16       Impact factor: 5.315

Review 3.  Proton magnetic resonance spectroscopy in oncology: the fingerprints of cancer?

Authors:  Roberto García-Figueiras; Sandra Baleato-González; Anwar R Padhani; Laura Oleaga; Joan C Vilanova; Antonio Luna; Juan Carlos Cobas Gómez
Journal:  Diagn Interv Radiol       Date:  2016 Jan-Feb       Impact factor: 2.630

4.  Can magnetic resonance spectroscopy differentiate endometrial cancer?

Authors:  Jie Zhang; Shifeng Cai; Changzhong Li; Xichao Sun; Xue Han; Chunrun Yang; Caixia Fu; Qingwei Liu; Yinghui Xin; Yuanyuan Zong
Journal:  Eur Radiol       Date:  2014-06-06       Impact factor: 5.315

5.  Preliminary observations and clinical value of lipid peak in high-grade uterine sarcomas using in vivo proton MR spectroscopy.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Eur Radiol       Date:  2013-06-06       Impact factor: 5.315

6.  Magnetic resonance spectroscopy associations with clinicopathologic features of estrogen-dependent endometrial cancer.

Authors:  Jie Zhang; Qingwei Liu; Jie Li; Zhiling Liu; Ximing Wang; Na Li; Zhaoqin Huang; Han Xu
Journal:  BMC Med Imaging       Date:  2022-07-18       Impact factor: 2.795

Review 7.  Imaging biomarkers for evaluating tumor response: RECIST and beyond.

Authors:  Ching-Chung Ko; Lee-Ren Yeh; Yu-Ting Kuo; Jeon-Hor Chen
Journal:  Biomark Res       Date:  2021-07-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.